1 / 12

CHEMOTHERAPY AND BLADDER CANCER

CHEMOTHERAPY AND BLADDER CANCER. Walter Stadler, MD, FACP University of Chicago. Anatomy as a Problem. One score and seven years ago…. The metastatic d. problem 1985 - MVAC first reported 1997 - Gemcitabine first reported to have activity GC found comparable to MVAC in 2000

cirila
Télécharger la présentation

CHEMOTHERAPY AND BLADDER CANCER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago

  2. Anatomy as a Problem

  3. One score and seven years ago… The metastatic d. problem • 1985 - MVAC first reported • 1997 - Gemcitabine first reported to have activity • GC found comparable to MVAC in 2000 • Response rates: • 50-55% CR +PR • 10% CR • OS 14 months • ~5% cured Sternberg et al., J Urol (1985) Stadler et al., JCO (1997) von der Maase et al., JCO (2000)

  4. For the Patient • Gemcitabine/cisplatin OR MVAC appropriate • Toxicities similar, but potential cardiac problems and mouth sores with MVAC • Major toxicities of both: • Low blood counts & risk for infection • Fatigue • Nausea • Neuropathy and hearing loss • Kidney damage

  5. Carboplatin instead of Cisplatin • More problems with low blood counts • Fewer kidney and neurologic problems • Probably less effective than Cisplatin • Significance in the metastatic setting debatable • Should not be used in peri-operative setting

  6. What if Initial Therapy is not Effective • No standard of care • Responses observed with paclitaxel, docetaxel, pemetrexed, etc, but not clear how meaningful these are for the patient • Clinical trial participation preferred

  7. N=317 pts • Enrolled from 1987 - 1998 • Muscle-invasive bladder cancer (stage T2 to T4a, all N0) • Primary objective: compare survival of patients treated with cystectomy alone vs treated with 3 cycles MVAC followed by cystectomy • Randomized phase III trial • Median follow-up 8.7 years (2003)

  8. Overall Survival • At five years, 57% alive in combination-therapy group, compared with 43% in cystectomy alone group (P=0.06) • --14% survival difference Grossman et al., NEJM (2003)

  9. Poor Adoption of These Data • Historical rates 5-10% • Retrospective review of patients with bladder cancer who underwent RC between 2003 and 2008 at University of Texas Southwestern: • Among 238 patients who underwent RC for bladder cancer, 145 had a preoperative clinical stage ≥T2 • Only 17% (25 of 145) received cisplatin-based neoadjuvant chemotherapy • Renal function was adequate in 97 (67%) of these patients Raj et al., Cancer (2011)

  10. Conclusions – Bladder Cancer • Peri-operative CDDP based chemotherapy improves survival • Best data in neoadjuvant setting • Underutilized • Ideal utilization rate unknown • >observed 5%; <80% • Gem/CDDP or MVAC is standard for metastatic disease • Carboplatin based therapies a reasonable option • No good standard for patients in whom initial therapy is not effective • Current standard is not good enough • I don’t want to give this talk in 20 yrs again • Clinical trial participation is key

More Related